Author

Nicholas H. Trageser

Observed name: Nicholas Trageser

Institution: Roswell Park Comprehensive Cancer Center

Observed institution: Roswell Park Comprehensive Cancer Center

OpenAlex ID: A5089901092

Signaling through TLR5 mitigates lethal radiation damage by neutrophil-dependent release of MMP-9

2021 · Craig M. Brackett, Kellee F. Greene, et al. · Cell Death Discovery · 12

Inhibition of the RAC/PAK Signaling Axis Enhances the Potency of MAPK Cascade Inhibitors Against Uveal Melanoma

2025 · Alexei A. Maslov, Nicholas H. Trageser, et al. · Biomolecules · 2

Entolimod, a clinical-stage TLR5 agonist, activates antitumor T cell immunity against liver and lung metastases through distinct mechanisms

2017 · Craig M Brackett, Bojidar Kojouharov, et al. · The Journal of Immunology · 2

Inhibitors of De Novo Guanylate Biosynthesis Enhance the Potency of MAPK Cascade Inhibitors Against Colorectal Cancer

2025 · Alexei A. Maslov, Nicholas H. Trageser, et al. · International Journal of Molecular Sciences

Naturally occurring T-cell-mediated antitumor immune response to LINE-1 antigens in mice that can be enhanced by vaccination and TLR5 agonist

2023 · Katerina I. Leonova, Anatoli S. Gleiberman, et al. · Research Square

Dormant senescence-prone cells (DSPC): a lifetime memory about systemic genotoxic stress

2022 · Katerina Leonova, Ilya Gitlin, et al. · Research Square

A Toll-like Receptor 5 agonist entolimod mitigates radiation damage through a neutrophil-dependent mechanism

2019 · Craig M Brackett, Kellee Greene, et al. · The Journal of Immunology

Works count: 7

Citation count: 16

H-index: 2

I10-index: 1